Latest Insider Transactions at Alkermes Plc. (ALKS)
This section provides a real-time view of insider transactions for Alkermes Plc. (ALKS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Alkermes plc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Alkermes plc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 18
2024
|
Christian Todd Nichols SVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,355
+8.53%
|
-
|
|
Feb 18
2024
|
Samuel Joseph Parisi VP, Finance (Interim PAO) |
SELL
Payment of exercise price or tax liability
|
Direct |
706
-11.9%
|
$22,592
$32.18 P/Share
|
|
Feb 18
2024
|
Samuel Joseph Parisi VP, Finance (Interim PAO) |
BUY
Exercise of conversion of derivative security
|
Direct |
2,034
+25.53%
|
-
|
|
Feb 18
2024
|
Blair Curtis Jackson EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,888
-2.61%
|
$124,416
$32.18 P/Share
|
|
Feb 18
2024
|
Blair Curtis Jackson EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,897
+5.64%
|
-
|
|
Feb 18
2024
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,308
-0.48%
|
$41,856
$32.18 P/Share
|
|
Feb 18
2024
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
4,448
+1.6%
|
-
|
|
Feb 18
2024
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,869
-1.21%
|
$59,808
$32.18 P/Share
|
|
Feb 18
2024
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
6,355
+3.96%
|
-
|
|
Feb 18
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,951
-4.08%
|
$126,432
$32.18 P/Share
|
|
Feb 18
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,897
+8.41%
|
-
|
|
Feb 18
2024
|
Iain Michael Brown SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,869
-1.73%
|
$59,808
$32.18 P/Share
|
|
Feb 18
2024
|
Iain Michael Brown SVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,355
+5.55%
|
-
|
|
Feb 15
2024
|
Cato T Laurencin Director |
SELL
Open market or private sale
|
Direct |
2,690
-15.06%
|
$83,390
$31.85 P/Share
|
|
Feb 15
2024
|
Cato T Laurencin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,690
+13.09%
|
$59,180
$22.52 P/Share
|
|
Feb 10
2024
|
Brian P Mckeon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,088
-4.49%
|
$29,376
$27.32 P/Share
|
|
Feb 10
2024
|
Brian P Mckeon Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,533
+15.76%
|
-
|
|
Feb 10
2024
|
David Angelo Daglio Jr. Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,088
-4.49%
|
$29,376
$27.32 P/Share
|
|
Feb 10
2024
|
David Angelo Daglio Jr. Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,533
+15.76%
|
-
|
|
Feb 08
2024
|
Blair Curtis Jackson EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
11,007
-7.29%
|
$286,182
$26.77 P/Share
|
|
Feb 08
2024
|
Blair Curtis Jackson EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,835
+19.62%
|
-
|
|
Feb 08
2024
|
Richard F Pops Director and CEO, Alkermes plc |
SELL
Payment of exercise price or tax liability
|
Direct |
91,757
-7.22%
|
$2,385,682
$26.77 P/Share
|
|
Feb 08
2024
|
Richard F Pops Director and CEO, Alkermes plc |
BUY
Grant, award, or other acquisition
|
Direct |
218,551
+14.67%
|
-
|
|
Feb 08
2024
|
Iain Michael Brown SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,137
-7.41%
|
$211,562
$26.77 P/Share
|
|
Feb 08
2024
|
Iain Michael Brown SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,012
+19.74%
|
-
|
|
Feb 08
2024
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
8,483
-5.43%
|
$220,558
$26.77 P/Share
|
|
Feb 08
2024
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Grant, award, or other acquisition
|
Direct |
28,240
+15.31%
|
-
|
|
Feb 08
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15,280
-14.8%
|
$397,280
$26.77 P/Share
|
|
Feb 08
2024
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
46,658
+31.13%
|
-
|
|
Feb 08
2024
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,183
-1.17%
|
$82,758
$26.77 P/Share
|
|
Feb 08
2024
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
BUY
Grant, award, or other acquisition
|
Direct |
21,485
+7.32%
|
-
|
|
Feb 08
2024
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,135
-11.63%
|
$211,510
$26.77 P/Share
|
|
Feb 08
2024
|
Christian Todd Nichols SVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
27,012
+27.86%
|
-
|
|
Dec 08
2023
|
Cato T Laurencin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,000
-6.18%
|
$25,000
$25.86 P/Share
|
|
Dec 08
2023
|
Cato T Laurencin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,163
+20.48%
|
-
|
|
Aug 03
2023
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
877
-0.68%
|
$23,679
$27.63 P/Share
|
|
Aug 03
2023
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
1,974
+1.51%
|
-
|
|
Jul 07
2023
|
Nancy Lynn Md Snyderman Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,430
-6.44%
|
$41,470
$29.88 P/Share
|
|
Jul 07
2023
|
Nancy Lynn Md Snyderman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,957
+21.15%
|
-
|
|
Jul 07
2023
|
Frank Anders Wilson Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,430
-6.56%
|
$41,470
$29.88 P/Share
|
|
Jul 07
2023
|
Frank Anders Wilson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,957
+21.47%
|
-
|
|
Jul 07
2023
|
Christopher I Wright Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,430
-16.44%
|
$41,470
$29.88 P/Share
|
|
Jul 07
2023
|
Christopher I Wright Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,957
+40.65%
|
-
|
|
Jul 07
2023
|
Nancy Wysenski Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,430
-6.56%
|
$41,470
$29.88 P/Share
|
|
Jul 07
2023
|
Nancy Wysenski Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,957
+21.47%
|
-
|
|
Jul 07
2023
|
Richard Gaynor Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,430
-6.56%
|
$41,470
$29.88 P/Share
|
|
Jul 07
2023
|
Richard Gaynor Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,957
+21.47%
|
-
|
|
Jul 07
2023
|
Cato T Laurencin Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,430
-10.64%
|
$41,470
$29.88 P/Share
|
|
Jul 07
2023
|
Cato T Laurencin Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,957
+30.72%
|
-
|
|
Jul 07
2023
|
Brian P Mckeon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,430
-6.77%
|
$41,470
$29.88 P/Share
|